Study of INCA036978 for blood cancers
Part of Blood & lymphatic, Cancer clinical trials.
This trial tests a new drug called INCA036978 for people with a group of blood cancers called myeloproliferative neoplasms (MPNs), including myelofibrosis, polycythemia vera, and essential thrombocythemia. It aims to see if the drug is safe and works well.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have a life expectancy of more than 6 months.
- You are willing to have bone marrow tests before and during the study.
- You have been diagnosed with Myelofibrosis, Polycythemia Vera, or Essential Thrombocythemia.
- You have not had any other cancer in the last 3 years.
- You have not had a stem cell transplant or plan to have one in the next 6 months.
- You have not had major bleeding or blood clots in the last 3 months.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new drug, INCA035784, for people with myeloproliferative neoplasms (MPNs), a group of blood cancers. It may help if your MPN is called myelofibrosis (MF) or essential thrombocythemia (ET) and has a specific genetic change (CALR mutation), and you've already tried other treatments.
This trial tests a new drug, INCA033989, alone or with ruxolitinib for people with certain blood cancers called myeloproliferative neoplasms (MPNs). It may help those with a specific genetic change (CALR mutation) who have not had success with other treatments.
This study tests a new drug called INCA033989 for people with a high-risk form of essential thrombocythemia (a blood disorder causing too many platelets) who have a specific genetic change called mutCALR. The trial compares this new drug to the best currently available treatments.
This is an early-stage study of inobrodib (CCS1477) for blood cancers like lymphoma, multiple myeloma, or acute myeloid leukemia that have returned or did not respond to standard treatment. It aims to see whether the drug is safe and can help control the cancer.
This study tests an experimental pill called PRT12396 for people with myeloproliferative neoplasms (MPN). It aims to see if the drug is safe and helps control the disease.
This trial tests a new drug called INCA036873, which targets CD70 on cancer cells, for people with advanced solid tumors or certain blood cancers that have not responded to prior treatments. The goal is to see if it is safe and effective against these tough-to-treat cancers.
Hear when a new Myeloproliferative Neoplasms trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.